APPENDIX 17


Central Pharmacy Service Level Sep-2014 through Dec-2014
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Receiver's Standard 80% of KOPs filled at CFP (<20% filled locally)
Stock Card Only
Stock Cards Only
ASP
CAC
CAL
CCC
CCI
CCWF
CEN
CHCF
CIM
CIW
CMC
CMF
COR
CRC
CTF
CVSP
DVI
FSP
FWF
HDSP
ISP
KVSP
LAC
MCSP
NKSP
PBSP
PVSP
RJD
SAC
SATF
SCC
SOL
SQ
SVSP
VSPW
WAS


Top 10 Drugs Purchased Sep-2014 Through Dec-2014
Sovaldi (HCV), $14,944,031
Harvoni (HCV), $4,636,986
Olysio (HCV), $4,289,842
Truvada (HIV), $2,930,728
Abilify (MH), $2,340,816
Lantus Insulin, $2,193,524
Atripla (HIV), $2,141,373
Fluticasone Propionate, $1,595,064
Divalproex, $1,434,417
Pegasys (HCV), $1,381,781
All Other Drugs, $39,125,524

Top 10 Therapeutic Categories Purchased Sep-2014 Through Dec-2014‡



‡The HCV category includes peginterferon, ribavirin, Victrelis, Incivek, Sovaldi, Olysio and Harvoni purchases. The ribavirin, Sovaldi, and Olysio purchases have been added to this category since the 26th Tri-Annual Report. Harvoni has been added to this category in the 28th Tri-Annual Report.

Note: the top 10 therapeutic categories represent $63,959,187 (83%) of the $77,048,910 total drugs purchased from the Prime Vendor Sep-2014 through Dec-2014